Continuous infusion of meropenem-vaborbactam for a KPC-3-producing Klebsiella pneumoniae bloodstream infection in a critically ill patient with augmented renal clearance.

Larcher, R ; Laffont-Lozes, P ; et al.

In: Infection, Jg. 51 (2023-12-01), Heft 6, S. 1835-1840

Online academicJournal

Zugriff:

Zum Volltext

Purpose: To demonstrate the feasibility of continuous infusion of meropenem-vaborbactam to optimize the treatment of carbapenem-resistant Enterobacterales.

Methods: Report of a case of a Klebsiella pneumoniae carbapenemase (KPC)-producing K. pneumoniae bloodstream infection comfirmed by whole genome sequencing and therapeutic drug monitoring (TDM) of meropenem.

Results: A patient with augmented renal clearance (ARC) went into septic shock caused by an ST11 KPC-3-producing K. pneumoniae bloodstream infection that was successfully treated with a continuous infusion of meropenem-vaborbactam at a dosage of 1 g/1 g q4h as a 4-h infusion. TDM confirmed sustained concentrations of meropenem ranging from 8 to 16 mg/L throughout the dosing interval.

Conclusion: Continuous infusion of meropenem-vaborbactam was feasible. It could be appropriate for optimizing the management of critically ill patients with ARC, as it resulted in antibiotic concentrations above the minimum inhibitory concentration for susceptible carbapenem-resistant Enterobacterales (up to 8 mg/L) throughout the dosing interval.

Titel:	Continuous infusion of meropenem-vaborbactam for a KPC-3-producing Klebsiella pneumoniae bloodstream infection in a critically ill patient with augmented renal clearance.
Autor/in / Beteiligte Person:	Larcher, R ; Laffont-Lozes, P ; Naciri, T ; Bourgeois, PM ; Gandon, C ; Magnan, C ; Pantel, A ; Sotto, A
Link:	Zum Volltext
Zeitschrift:	Infection, Jg. 51 (2023-12-01), Heft 6, S. 1835-1840
Veröffentlichung:	2011- : Heidelberg : Springer Heidelberg ; <i>Original Publication</i>: München, Verlagsgesellschaft Otto Spatz., 2023
Medientyp:	academicJournal
ISSN:	1439-0973 (electronic)
DOI:	10.1007/s15010-023-02055-2
Schlagwort:	Humans Meropenem therapeutic use Critical Illness Anti-Bacterial Agents pharmacology Anti-Bacterial Agents therapeutic use beta-Lactamases genetics Bacterial Proteins genetics Drug Combinations Microbial Sensitivity Tests Klebsiella pneumoniae Sepsis
Sonstiges:	Nachgewiesen in: MEDLINE Sprachen: English Publication Type: Case Reports; Journal Article Language: English [Infection] 2023 Dec; Vol. 51 (6), pp. 1835-1840. <i>Date of Electronic Publication: </i>2023 Jun 06. MeSH Terms: Klebsiella pneumoniae* ; Sepsis* ; Humans ; Meropenem / therapeutic use ; Critical Illness ; Anti-Bacterial Agents / pharmacology ; Anti-Bacterial Agents / therapeutic use ; beta-Lactamases / genetics ; Bacterial Proteins / genetics ; Drug Combinations ; Microbial Sensitivity Tests References: Lancet Infect Dis. 2014 Jun;14(6):498-509. (PMID: 24768475) ; Lancet. 2022 Feb 12;399(10325):629-655. (PMID: 35065702) ; Am J Respir Crit Care Med. 2016 Sep 15;194(6):681-91. (PMID: 26974879) ; Microb Genom. 2021 Jul;7(7):. (PMID: 34279213) ; Antimicrob Agents Chemother. 2016 Jul 22;60(8):4734-42. (PMID: 27216076) ; Microbiol Spectr. 2023 Feb 14;11(1):e0264722. (PMID: 36622246) ; Int J Antimicrob Agents. 2022 May;59(5):106569. (PMID: 35288259) ; Infect Drug Resist. 2019 Mar 20;12:603-611. (PMID: 31114256) ; J Antimicrob Chemother. 2010 May;65(5):1073-5. (PMID: 20176578) ; Antibiotics (Basel). 2020 Nov 13;9(11):. (PMID: 33202755) ; Intensive Care Med. 2020 Jun;46(6):1127-1153. (PMID: 32383061) ; Infect Dis Ther. 2020 Dec;9(4):769-784. (PMID: 33025557) ; Front Microbiol. 2016 Jun 28;7:1000. (PMID: 27446040) ; Antimicrob Agents Chemother. 2022 Sep 20;66(9):e0044722. (PMID: 35980232) Contributed Indexing: Keywords: Augmented renal clearance; Continuous infusion; KPC-3-producing Klebsiella pneumoniae; Meropenem–vaborbactam; ST11; ST147 Substance Nomenclature: FV9J3JU8B1 (Meropenem) ; EC 3.5.2.6 (carbapenemase) ; 1C75676F8V (vaborbactam) ; 0 (Anti-Bacterial Agents) ; EC 3.5.2.6 (beta-Lactamases) ; 0 (Bacterial Proteins) ; 0 (Drug Combinations) Entry Date(s): Date Created: 20230605 Date Completed: 20231127 Latest Revision: 20231127 Update Code: 20240513 PubMed Central ID: PMC10665223

Klicken Sie ein Format an und speichern Sie dann die Daten oder geben Sie eine Empfänger-Adresse ein und lassen Sie sich per Email zusenden.

BibTeX Citavi, JabRef, u.a.
(Literaturverwaltung)

PDF kein Volltext!
(Merkzettel, Notizen)

RIS Endnote, Citavi u.a.
(Literaturverwaltung)

MODS
(XML zur Weiterverarbeitung)

oder

Wählen Sie das für Sie passende Zitationsformat und kopieren Sie es dann in die Zwischenablage, lassen es sich per Mail zusenden oder speichern es als PDF-Datei.

Gewünschter Zitations-Stil:

oder

Bitte prüfen Sie, ob die Zitation formal korrekt ist, bevor Sie sie in einer Arbeit verwenden. Benutzen Sie gegebenenfalls den "Exportieren"-Dialog, wenn Sie ein Literaturverwaltungsprogramm verwenden und die Zitat-Angaben selbst formatieren wollen.